Morgan Stanley Inmune Bio, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 84,464 shares of INMB stock, worth $608,985. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,464

Previous 155,126 45.55%

Holding current value

$608,985

Previous $724,000 8.98%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.93 - $10.48 $348,363 - $740,537	-70,662 Reduced 45.55%	84,464 $659,000
Q4 2024 Feb 14, 2025	BUY	$4.4 - $6.43 $277,120 - $404,974	62,982 Added 68.35%	155,126 $724,000
Q3 2024 May 14, 2025	BUY	$4.86 - $9.86 $309,917 - $628,762	63,769 Added 224.74%	92,144 $496,000
Q3 2024 Nov 14, 2024	BUY	$4.86 - $9.86 $309,917 - $628,762	63,769 Added 224.74%	92,144 $496,000
Q2 2024 May 14, 2025	SELL	$7.15 - $11.84 $906,269 - $1.5 Million	-126,751 Reduced 81.71%	28,375 $250,000
Q2 2024 Oct 17, 2024	BUY	$7.15 - $11.84 $6,406 - $10,608	896 Added 3.26%	28,375 $250,000
Q2 2024 Aug 14, 2024	BUY	$7.15 - $11.84 $6,406 - $10,608	896 Added 3.26%	28,375 $250,000
Q1 2024 Oct 17, 2024	SELL	$10.53 - $14.01 $9,434 - $12,552	-896 Reduced 3.16%	27,479 $322,000
Q1 2024 Aug 16, 2024	BUY	$10.53 - $14.01 $154,538 - $205,610	14,676 Added 114.63%	27,479 $322,000
Q1 2024 May 15, 2024	BUY	$10.53 - $14.01 $154,538 - $205,610	14,676 Added 114.63%	27,479 $322,000
Q4 2023 Aug 16, 2024	SELL	$6.6 - $11.52 $102,775 - $179,389	-15,572 Reduced 54.88%	12,803 $144,000
Q4 2023 Feb 13, 2024	BUY	$6.6 - $11.52 $57,565 - $100,477	8,722 Added 213.72%	12,803 $144,000
Q3 2023 Nov 15, 2023	SELL	$6.61 - $10.9 $6,034 - $9,951	-913 Reduced 18.28%	4,081 $27,000
Q2 2023 Aug 14, 2023	BUY	$6.5 - $10.09 $1,150 - $1,785	177 Added 3.67%	4,994 $45,000
Q1 2023 May 15, 2023	BUY	$6.01 - $10.18 $10,992 - $18,619	1,829 Added 61.21%	4,817 $31,000
Q4 2022 Feb 14, 2023	SELL	$6.13 - $7.96 $772,453 - $1 Million	-126,012 Reduced 97.68%	2,988 $18,000
Q3 2022 Nov 14, 2022	SELL	$6.04 - $10.44 $478,863 - $827,704	-79,282 Reduced 38.06%	129,000 $800,000
Q2 2022 Oct 27, 2022	SELL	$5.48 - $8.97 $505,250 - $827,025	-92,199 Reduced 30.68%	208,282 $1.84 Million
Q2 2022 Aug 15, 2022	SELL	$5.48 - $8.97 $505,250 - $827,025	-92,199 Reduced 30.68%	208,282 $1.84 Million
Q1 2022 Oct 27, 2022	BUY	$6.42 - $11.39 $591,917 - $1.05 Million	92,199 Added 44.27%	300,481 $2.53 Million
Q1 2022 May 13, 2022	SELL	$6.42 - $11.39 $500,798 - $888,488	-78,006 Reduced 20.61%	300,481 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$9.97 - $20.38 $3.53 Million - $7.21 Million	353,856 Added 1436.63%	378,487 $3.86 Million
Q3 2021 Nov 15, 2021	BUY	$14.13 - $27.85 $348,036 - $685,973	24,631 New	24,631 $478,000

Others Institutions Holding INMB

# of Institutions

Shares Held

6.87M

Call Options Held

202K

Put Options Held

104K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $129M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account